Patients have a right to decline or withdraw LVADs. Informed consent and shared decision making is not easy, however, with treatments that are high risk, high reward.
AMA J Ethics. 2019;21(5):E394-400. doi:
10.1001/amajethics.2019.394.
Ruth M. Farrell, MD, MA, Marsha Michie, PhD, Christopher T. Scott, PhD, Rebecca Flyckt, MD, and Mary LaPlante, MD
One reason for neglect of women’s health as patients and subjects has been restrictions on uterine transfer of modified human embryos, a boundary that has now been crossed.
AMA J Ethics. 2019;21(12):E1071-1078. doi:
10.1001/amajethics.2019.1071.
Clarissa G. Barnes, Frederick L. Brancati, MD, MHS, and Tiffany L. Gary, PhD, MHS
To combat the rising incidence of type 2 diabetes, New York City requires laboratories with electronic reporting capacity to upload data on hemoglobin A1c measurements to a city department of health registry.
Physicians, committees, and guardians all make decisions for unrepresented patients in the US. This article considers a “tiered” approach as an alternative.
AMA J Ethics. 2019;21(7):E587-593. doi:
10.1001/amajethics.2019.587.
When patients are unable to express their wishes and do not have surrogates or advance directives, which and whose values should inform decision making for them? We discuss ethical complexities of caring for unrepresented patients.